stockrow
Friday 6 November 2026
Export AZR’s income statement to Excel — free account
Azora Therapeutics, Inc.
- EPS
- −150.0%
- Free cash flow
- −263.7%
Quarter to June 2026, against a year earlier
3.76
0.05
+1.35%
Follow AZR
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 352.60% | (265.95%) | (170.72%) | (155.00%) |
+8 more TTM periods Free account |
|
| (322.10%) | (179.08%) | (136.15%) | (130.15%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(243.64%) | (235.99%) | (166.75%) | (208.64%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.41) | (4.76) | (5.79) | (7.47) | |
Free Cash Flow |
(11.13) | (6.52) | (6.38) | (6.62) | |
Capital Expenditures |
— | — | 0.12 | — | |
| Other line items | |||||
Cash ROIC |
115.18% | (78.54%) | (57.15%) | (72.68%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.93) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.19 | 0.84 | 0.81 | 0.82 | |
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | 0.00 | 129.22 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.41) | (4.76) | (5.90) | (7.47) | |
Capex per Share |
0.00 | 0.00 | 0.11 | 0.00 | |
Capex to Sales |
— | — | 0.00 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026